Innate Total Current Liabilities from 2010 to 2025
| IPHA Stock | USD 1.97 0.16 8.84% |
Total Current Liabilities | First Reported 2009-12-31 | Previous Quarter 38.2 M | Current Value 38.2 M | Quarterly Volatility 68 M |
Check Innate Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innate Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.1 M, Interest Expense of 1.1 M or Selling General Administrative of 13.7 M, as well as many indicators such as Price To Sales Ratio of 3.47, Dividend Yield of 0.0023 or PTB Ratio of 3.47. Innate financial statements analysis is a perfect complement when working with Innate Pharma Valuation or Volatility modules.
Innate | Total Current Liabilities |
Latest Innate Pharma's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Innate Pharma over the last few years. Total Current Liabilities is an item on Innate Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Innate Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Innate Pharma's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Innate Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Innate Total Current Liabilities Regression Statistics
| Arithmetic Mean | 55,250,176 | |
| Geometric Mean | 35,345,920 | |
| Coefficient Of Variation | 89.40 | |
| Mean Deviation | 34,682,118 | |
| Median | 46,694,000 | |
| Standard Deviation | 49,394,611 | |
| Sample Variance | 2439.8T | |
| Range | 194.5M | |
| R-Value | 0.33 | |
| Mean Square Error | 2332T | |
| R-Squared | 0.11 | |
| Significance | 0.21 | |
| Slope | 3,408,134 | |
| Total Sum of Squares | 36597.4T |
Innate Total Current Liabilities History
About Innate Pharma Financial Statements
Innate Pharma stakeholders use historical fundamental indicators, such as Innate Pharma's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Innate Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Innate Pharma's assets and liabilities are reflected in the revenues and expenses on Innate Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Innate Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 45.6 M | 48.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Innate Pharma Correlation against competitors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth (0.69) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.